ImmunoNova

ImmunoNova is a Brazilian biotechnology company dedicated to developing advanced immunotherapies for cancer and infectious diseases. The company's primary asset is P-MAPA, a unique immunomodulator derived from Aspergillus oryzae that functions as a Toll-like receptor (TLR) agonist. P-MAPA has demonstrated significant potential in stimulating the innate immune response, particularly in treating non-muscle invasive bladder cancer and various viral infections. ImmunoNova collaborates closely with the Farmabrasilis research network and academic institutions like UNICAMP to advance its clinical pipeline. The company focuses on creating cost-effective treatments that address significant unmet medical needs in global health. Its research also extends to neglected tropical diseases such as leishmaniasis.